SmithKline Clear NicoDerm CQ Latest Effort Against Private Label Rivals
This article was originally published in The Tan Sheet
Executive Summary
The introduction of Clear NicoDerm CQ Patch will attract a substantial number of first-time users - especially among minority populations - to the smoking cessation category, marketer SmithKline Beecham predicted based on recent consumer research.
You may also be interested in...
SB Aquafresh 17% Sales Increase Freshens Up Second Quarter Results
"Outstanding" U.S. activity by the Aquafresh brand in the second quarter contributed to a 17% spike in worldwide sales for the line and an 8% rise in global oral care sales to $255 mil., SmithKline Beecham CEO Jean-Paul Garnier, PhD, announced during a July 25 conference call.
Hatch/Waxman Act Allows Potential Copyright Infringement - Court
A New York City federal appeals court unanimously ruled in favor of Watson Pharmaceuticals April 4, lifting a preliminary injunction against the sale of its generic OTC nicotine polacrilex gum and dismissing SmithKline Beecham Consumer Healthcare's copyright infringement action.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC